Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rexer

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Aktuelle Urologie|March 26, 2020
H Rexer, S Schmid, A Merseburger
Aktuelle Urologie|May 23, 2018
H Rexer, M Graefen, C Wülfing
Der Urologe. Ausg. A|June 16, 2017
[An open single-arm phase II monotherapy study of pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (Keynote 427) - AN 40/16 of the AUO]H Rexer, C Doehn, J Bedke
Der Urologe. Ausg. A|May 25, 2017
[Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma]H Rexer, T Steiner, L Bergmann
Der Urologe. Ausg. A|November 18, 2005
[Study participation in urological specialty practices]G Geiges, A Böhle, H Rexer
Aktuelle Urologie|November 27, 2019
H Rexer, C Doehn, A Merseburger
Aktuelle Urologie|August 10, 2019
H Rexer, A Merseburger, M Bögemann
Aktuelle Urologie|August 30, 2019
H Rexer, M Graefen, A Merseburger
Aktuelle Urologie|February 5, 2020
H Rexer, J Bedke, F Imkamp
Der Urologe. Ausg. A|March 3, 2017
[First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO]H Rexer, Th Steiner, V Grünwald
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Aktuelle Urologie|March 26, 2020
H Rexer, S Schmid, A Merseburger
Aktuelle Urologie|May 23, 2018
H Rexer, M Graefen, C Wülfing
Der Urologe. Ausg. A|June 16, 2017
[An open single-arm phase II monotherapy study of pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (Keynote 427) - AN 40/16 of the AUO]H Rexer, C Doehn, J Bedke
Der Urologe. Ausg. A|May 25, 2017
[Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma]H Rexer, T Steiner, L Bergmann
Der Urologe. Ausg. A|November 18, 2005
[Study participation in urological specialty practices]G Geiges, A Böhle, H Rexer
Aktuelle Urologie|November 27, 2019
H Rexer, C Doehn, A Merseburger
Aktuelle Urologie|August 10, 2019
H Rexer, A Merseburger, M Bögemann
Aktuelle Urologie|August 30, 2019
H Rexer, M Graefen, A Merseburger
Aktuelle Urologie|February 5, 2020
H Rexer, J Bedke, F Imkamp
Der Urologe. Ausg. A|March 3, 2017
[First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO]H Rexer, Th Steiner, V Grünwald
Pageof 11